Symbiotec Pharma
Stock surges post management comments in the interview
Key takeaways
- Revenue by FY30-31 could by a multiple of current levels
- New Capex, on Asset Base could support revenues of >2000 Cr
- CDMO & Injectibles will be larger contribution to sales by FY30
- New categories are at 10pp higher gross margins and 3-7pp higher EBITDA margins
#StockMarket #NewListing #Symbiotec x.com/CNBCTV18News/s…
- Symbiotec Pharma Stock surges post management comments in the interview Key takeaways - Revenue by FY30-31 could by a multiple of current levels - New Capex, on Asset Base could support revenues of >2000 Cr - CDMO & Injectibles will be larger contribution to sales by FY30 - New categories are at 10pp higher gross margins and 3-7pp higher EBITDA margins #StockMarket #NewListing #Symbiotec x.com/CNBCTV18News/s…
Why did he sell then? That too at a pe> 56, if its reported earnings is correct.